250 related articles for article (PubMed ID: 19903426)
21. The role and advances of immunomodulator therapy for inflammatory bowel disease.
Nielsen OH; Coskun M; Steenholdt C; Rogler G
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):177-89. PubMed ID: 25101818
[TBL] [Abstract][Full Text] [Related]
22. Optimization of conventional therapy in patients with IBD.
Taylor KM; Irving PM
Nat Rev Gastroenterol Hepatol; 2011 Oct; 8(11):646-56. PubMed ID: 21970871
[TBL] [Abstract][Full Text] [Related]
23. Management of inflammatory bowel disease with
D'Aoust J; Battat R; Bessissow T
World J Gastroenterol; 2017 Jul; 23(27):4986-5003. PubMed ID: 28785153
[TBL] [Abstract][Full Text] [Related]
24. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
Andrews JM; Travis SP; Gibson PR; Gasche C
Aliment Pharmacol Ther; 2009 Mar; 29(5):459-69. PubMed ID: 19077129
[TBL] [Abstract][Full Text] [Related]
25. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
26. Medical therapy of inflammatory bowel disease for the 21st century.
Robinson M
Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
[TBL] [Abstract][Full Text] [Related]
27. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
28. De-escalation of medical therapy in inflammatory bowel disease.
Frias Gomes C; Chapman TP; Satsangi J
Curr Opin Pharmacol; 2020 Dec; 55():73-81. PubMed ID: 33160250
[TBL] [Abstract][Full Text] [Related]
29. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
30. Classical and recent advances in the treatment of inflammatory bowel diseases.
Sales-Campos H; Basso PJ; Alves VB; Fonseca MT; Bonfá G; Nardini V; Cardoso CR
Braz J Med Biol Res; 2015 Feb; 48(2):96-107. PubMed ID: 25466162
[TBL] [Abstract][Full Text] [Related]
31. Treatment of inflammatory bowel disease (IBD).
Pithadia AB; Jain S
Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
[TBL] [Abstract][Full Text] [Related]
32. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
van Hoeve K; Vermeire S
Paediatr Drugs; 2020 Oct; 22(5):449-461. PubMed ID: 32797366
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory bowel disease therapy: an update.
Shah SA; Peppercorn MA
Compr Ther; 1995 Jun; 21(6):296-302. PubMed ID: 7664541
[TBL] [Abstract][Full Text] [Related]
34. Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD).
Raithel M; Nägel A; Zopf Y; deRossi T; Stengel Ch; Hagel A; Kressel J; Hahn EG; Konturek P
Inflamm Res; 2010 Mar; 59 Suppl 2():S257-8. PubMed ID: 20087628
[No Abstract] [Full Text] [Related]
35. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
36. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.
Mahadevan U; McConnell RA; Chambers CD
Gastroenterology; 2017 Feb; 152(2):451-462.e2. PubMed ID: 27769809
[TBL] [Abstract][Full Text] [Related]
37. Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD.
Markowitz J; Daum F; Cohen SA; Glassman M; Holmes RD; Piccoli D; Rossi TM; Treem WR; Ulshen MH; Winter HS
J Pediatr Gastroenterol Nutr; 1991 May; 12(4):411-23. PubMed ID: 1678006
[TBL] [Abstract][Full Text] [Related]
38. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.
Panaccione R; Steinhart AH; Bressler B; Khanna R; Marshall JK; Targownik L; Afif W; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C; Bernstein CN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1680-1713. PubMed ID: 30853616
[TBL] [Abstract][Full Text] [Related]
39. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Tang J; Sharif O; Pai C; Silverman AL
Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
[TBL] [Abstract][Full Text] [Related]
40. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
